25/100B40.640
USD
-0.02
(-0.05%)
Market Open
Last updated: · Delayed 15 min
Roivant Sciences stock buybacks 2019–2026What are stock buybacks? A stock buyback is a company buying its own shares on the market. With fewer shares left, each remaining share owns a bigger part of the company.
Roivant Sciences spent 74.47M USD buying back its shares in Q2 FY2026, the three months to 30 September 2026, with no change to compare on the same quarter a year before. Roivant Sciences spent 319.50M USD buying back its shares in fiscal year 2025, down 75.3% on the year before.
Last updated 10 Nov 2026 · Next report 5 Feb 2027
Stock buybacks
Growth
| Fiscal year | Period ending | Stock buybacks | Growth | Dividends paid | Free cash flow |
|---|---|---|---|---|---|
| TTM | 30 Sept 2026 | — | — | — | — |
| FY2025 | 31 Mar 2026 | 319.50M | -75.29% | 0.00 | -758.56M |
| FY2024 | 31 Mar 2025 | 1.29B | — | 0.00 | -844.05M |
| FY2023 | 31 Mar 2024 | 0.00 | — | 6.00M | -766.65M |
| FY2022 | 31 Mar 2023 | 0.00 | — | 0.00 | -856.08M |
| FY2021 | 31 Mar 2022 | 0.00 | — | 0.00 | -695.17M |
| FY2020 | 31 Mar 2021 | 0.00 | -100.00% | 0.00 | -557.94M |
| FY2019 | 31 Mar 2020 | 1.19B | — | 0.00 | -766.75M |
| Quarter | Period ending | Stock buybacks | Growth on a year before | Dividends paid | Free cash flow |
|---|---|---|---|---|---|
| Q2 FY2026 | 30 Sept 2026 | 74.47M | — | 0.00 | 594.21M |
| Q1 FY2026 | 30 Jun 2026 | 206.73M | -0.75% | 0.00 | -263.81M |
| Q4 FY2025 | 31 Mar 2026 | 111.21M | -62.36% | 0.00 | -165.08M |
| Q3 FY2025 | 31 Dec 2025 | 0.00 | -100.00% | 0.00 | — |
| Q2 FY2025 | 30 Sept 2025 | 0.00 | -100.00% | 0.00 | -193.51M |
| Q1 FY2025 | 30 Jun 2025 | 208.29M | -67.88% | 0.00 | -208.42M |
| Q4 FY2024 | 31 Mar 2025 | 295.45M | — | 0.00 | -173.38M |
| Q3 FY2024 | 31 Dec 2024 | 243.35M | — | 0.00 | -209.08M |
| Q2 FY2024 | 17 Sept 2024 | 106.05M | — | 0.00 | -267.80M |
| Q1 FY2024 | 30 Jun 2024 | 648.39M | — | 0.00 | -193.79M |
| Q4 FY2023 | 31 Mar 2024 | 0.00 | — | 0.00 | -108.81M |
| Q3 FY2023 | 31 Dec 2023 | 0.00 | — | 0.00 | -210.81M |
| Q2 FY2023 | 30 Sept 2023 | 0.00 | — | 6.00M | -196.70M |
| Q1 FY2023 | 30 Jun 2023 | 0.00 | — | 0.00 | -250.34M |
| Q4 FY2022 | 31 Mar 2023 | 0.00 | — | 0.00 | -180.71M |
| Q3 FY2022 | 31 Dec 2022 | 0.00 | — | 0.00 | -223.10M |
Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.
The money spent buying back the company's own shares in each period, from the cash flow statement.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow
Common questions about Roivant Sciences's buybacks
Source: Financial Modeling Prep